Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 26, 2024 06:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
March 21, 2024 07:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
November 13, 2023 07:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split
October 30, 2023 12:00 ET
|
Catalyst Biosciences, Inc.
The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE...
Catalyst Biosciences Provides Corporate Update
February 28, 2023 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the...
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
December 27, 2022 07:00 ET
|
Catalyst Biosciences, Inc.
Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5...
Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share
September 01, 2022 16:05 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the...
Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share
August 25, 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared...
Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation
August 19, 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that JDS1, LLC, one of the Company’s...
Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results
August 15, 2022 16:05 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second...